Own CSL (ASX:CSL) shares? Here's how the $17bn Vifor Pharma acquisition will boost its growth

Here's what you need to know about the Vifor Pharma acquisition…

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biotherapeutics giant CSL Limited (ASX: CSL) recently announced the acquisition of Vifor Pharma for $17 billion. While its shares have not fared overly well since then, the transaction is expected to be a boost to its long term growth.

But just how much of a boost? To find out, I thought I would take a look at what analysts are saying about this massive acquisition.

The Vifor Pharma acquisition

CSL has signed an agreement to acquire Swiss biotech giant Vifor Pharma for US$12.3 billion (A$17.2 billion) in cash.

Management expects the deal to expand its leadership across an attractive portfolio focused on renal disease and iron deficiency. In addition, it highlights that Vifor has a high quality pipeline and complements CSL's existing therapeutic focus areas. These include Haematology, Thrombosis, Cardiovascular, and Transplant.

The response

Commenting on the acquisition, Goldman Sachs said: "The transaction expands its blood products franchise and provides exposure to a growing renal disease market (>US$25bn by 2026), where the prevalence of Chronic Kidney Disease (CKD) is expected to grow at +8% pa. Vifor's product portfolio also has broad complementarities to CSL's development pipeline, notably CSL112 in reducing the incidence of recurrent cardiovascular episodes and CSL889 in treating Sickle Cell Anaemia."

Goldman notes that the deal is expected to boost CSL's earnings in the coming years.

It commented: "The transaction is expected to be low-to-mid teens NPATA per share accretive in the first full year of CSL ownership, including US$75m full rate cost synergies. The synergies are expected to be phased in a 3-year period post acquisition close."

This sentiment was echoed by the team at Citi. It said: "We calculate the acquisition to be ~9% accretive to NPATA per share (NPAT before acquisition-related amortization) – a proxy for cash flow. Including amortization, the transaction is expected to be "modestly accretive" to EPS."

In light of the above, Citi is forecasting earnings per share of $6.92 in FY 2022, $9.16 in FY 2023, and then $10.27 in FY 2024.

Are CSL's shares in the buy zone?

Goldman Sachs is helping CSL with its transaction. As a result, it is unable to provide a recommendation at this stage.

However, Citi can make recommendations and currently has a buy rating and $340.00 price target on CSL's shares. Based on its current share price, this suggests potential upside of 21% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,
Healthcare Shares

Here's why ASX 200 health insurance shares like Medibank are being trounced today

Investors are feeling a bit sick after the latest update.

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Record Highs

Superstar ASX 200 healthcare stock snags record high amid $32 million deal

The second multi-million-dollar deal in less than two weeks.

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Here's why a leading fund manager is excited by this ASX healthcare share

WAM thinks this stock is capable of producing good returns.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence (AI)
Share Gainers

Guess which ASX biotech stock just rocketed 25% on big US news

Here are all the details.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Fundie bullish on CSL shares after praising the 'special business'

Earnings growth justifies current valuations, these experts say.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Guess which ASX 200 healthcare stock is charging higher following FDA update

What is getting investors excited today? Let's find out.

Read more »

Two happy scientists analysing test results.
52-Week Highs

3 ASX All Ords health care shares that reached 52-week peaks today

These health care companies finished the week on a positive note.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

2 ASX healthcare shares rocketing over 16% on Big US news

These companies are making their shareholders smile on Thursday. But why?

Read more »